Today, Servier Pharmaceutics acquired the worldwide rights to BN104, a potential best-in-class precision therapy for AML and ALL, from BioNova Pharmaceuticals.

BN104 is a menin inhibitor and is currently in a Phase 1/2 clinical trial to evaluate the drug as a potential treatment for AML and ALL. The U.S. Food and Drug Administration (FDA) granted BN104 Fast Track Designation and Orphan Drug Status in the second half of 2023.

“With deep expertise in precision medicine and hematological malignancies, this asset acquisition is another step forward in advancing our leadership in leukemias and delivering life changing innovation to patients in need,” said Walid Kamoun, Global Head of R&D Oncology. “Servier brings extensive scientific expertise along with a proven history in the global development of targeted oncology treatments, and we are well positioned to maximize the potential of BN104 to patients globally.”

A Phase 2 pivotal trial is already underway, and Servier plans to initiate a global trial in a similar setting in 2027.

Menin inhibitors are a type of targeted therapy that block the activity of a protein called menin, which is involved in regulating gene expression and cell growth. In the case of leukemia, menin supports abnormal gene activity.

Under the terms of the agreement, Servier received exclusive worldwide rights to develop and commercialize BN104 in all potential indications and territories. The deal is subject to customary closing conditions.